Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients

Weijl, N.I.; Hopman, G.D.; Wipkink-Bakker, A.; Lentjes, Eef G.W.M.; Berger, Howard; Cleton, F. J.; Osanto, Susanne

doi:10.1023/a:1008407014084

Cited by 190 publications

(125 citation statements)

References 19 publications

Supporting

Mentioning

114

Contrasting

Unclassified

Order By: Relevance

“…Weijl et al (1998) found that chemotherapy with cisplatin reduces the patient's plasma antioxidant levels, demonstrating that free radical production occurs during treatment. Antioxidant administration does not appear to interfere in the antitumor effect of antineoplastics as these drugs destroy cancer cells through other mechanisms that do not involve the action of free radicals.…”

Section: Discussionmentioning

confidence: 99%

Antigenotoxic and antimutagenic effects of glutamine supplementation on mice treated with cisplatin

Pesarini¹,

Sg²,

Ap³

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We evaluated the effects of glutamine on clastogenic and genotoxic damage prevention caused by the administration of cisplatin. 4821©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 13 (3): 4820-4830 (2014) Glutamine prevents DNA damage Forty Swiss mice were divided into 8 experimental groups: G1 and G2, which were control groups; G3, G4, and G5, which were administered [2 doses of glutamine (orally)] separated by a 24-h period (150, 300, and 600 mg/kg, respectively), and a dose of phosphate-buffered saline by intraperitoneal injection; G6, G7, and G8, which were treated in the same manner as the previous groups, but received cisplatin rather than phosphate-buffered saline. The antimutagenicity groups showed damage reduction percentages of 79.05, 80.00, and 94.27% at the time point T1, 53.18, 67.05, and 64.74 at time point T2 for the 150, 300, and 600 mg/kg doses of glutamine, respectively. Antigenotoxic activity was evident for all 3 doses with damage reduction percentages of 115.05, 119.06, and 114.38 for the doses of glutamine of 150, 300, and 600 mg/ kg, respectively. These results suggest that further studies are needed to confirm the clastogenic activity of glutamine. However, our results may lead to rational strategies for supplementation of this antioxidant as an adjuvant in cancer treatment or for preventing genomic lesions.

show abstract

Section: Discussionmentioning

confidence: 99%

Antigenotoxic and antimutagenic effects of glutamine supplementation on mice treated with cisplatin

Pesarini¹,

Sg²,

Ap³

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…Many chemotherapeutic agents, including cisplatin, are potent pro-oxidative stressors [42,43]. Notably, the infusion of NAC, a potent antioxidant, which, when administered as monotherapy did not significantly affect overall angiogenesis.…”

Section: Discussionmentioning

confidence: 99%

On metronomic chemotherapy: Modulation of angiogenesis mediated by VEGE-A

2006

View full text Add to dashboard Cite

“…Cancer pathogenesis and the administration of anticancer treatment are associated with oxidative stress [52][53][54]. Moreover, antioxidant balance is thought to be disturbed in association with the toxicity of anticancer therapy.…”

Section: Discussionmentioning

confidence: 99%

Neoadjuvant combination therapy with trastuzumab in a breast cancer patient with synchronous rectal carcinoma: a case report and biomarker study

et al. 2017

View full text Add to dashboard Cite

Abstract:We report a patient who presented with synchronous second primary human epidermal growth factor receptor (HER)-2-positive breast cancer and rectal cancer that both required simultaneous neoadjuvant therapy. A modified regimen combining anti-HER-2 monoclonal antibody trastuzumab with chemotherapy and external beam radiation was selected. An organ-preserving surgical procedure was possible both in the breast and the rectum. Citrulline decreased rapidly after the start of the treatment, and then gradually returned to pre-treatment levels after the completion of chemoradiation. Urinary neopterin concentrations exhibited a fluctuating course. Both serum neopterin and C-reactive protein concentrations were more or less stable during the initial administration of trastuzumab, paclitaxel and carboplatin and then increased steeply during chemoradiation and subsequently declined to pre-treatment levels during the weekly trastuzumab administration. Changes were observed in the serum retinol concentrations. A decline in lymphocyte counts was accompanied by marked changes in peripheral blood cell count-derived ratios. The present case report demonstrates a successful combination of two neoadjuvant regimens in a patient with two synchronous different second primary tumors. Data from this case also illustrate the use of biomarkers for monitoring of intensive therapeutic regimens in medical and radiation oncology.

show abstract

Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients

Cited by 190 publications

References 19 publications

Antigenotoxic and antimutagenic effects of glutamine supplementation on mice treated with cisplatin

Antigenotoxic and antimutagenic effects of glutamine supplementation on mice treated with cisplatin

On metronomic chemotherapy: Modulation of angiogenesis mediated by VEGE-A

Neoadjuvant combination therapy with trastuzumab in a breast cancer patient with synchronous rectal carcinoma: a case report and biomarker study

Contact Info

Product

Resources

About